Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.

IF 2.8 4区医学 Q2 ONCOLOGY

Medical Oncology Pub Date : 2024-10-14 DOI:10.1007/s12032-024-02529-9

Saade Abdalkareem Jasim, Abdulrahman T Ahmed, Aziz Kubaev, Ashishkumar Kyada, Mohammad Y Alshahrani, Shilpa Sharma, Hussein Riyadh Abdul Kareem Al-Hetty, Raghav Vashishth, Ashish Singh Chauhan, Munther Kadhim Abosaoda

{"title":"Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.","authors":"Saade Abdalkareem Jasim, Abdulrahman T Ahmed, Aziz Kubaev, Ashishkumar Kyada, Mohammad Y Alshahrani, Shilpa Sharma, Hussein Riyadh Abdul Kareem Al-Hetty, Raghav Vashishth, Ashish Singh Chauhan, Munther Kadhim Abosaoda","doi":"10.1007/s12032-024-02529-9","DOIUrl":null,"url":null,"abstract":"<p><p>MicroRNAs (miRNAs) are conserved non-protein-coding RNAs that are naturally present in organisms and can control gene expression by suppressing the translation of mRNA or causing the degradation of mRNA. MicroRNAs are highly concentrated in the PI3K/AKT pathway, and abnormal activation of the PI3K/AKT pathway plays a role in cancer progression. The AKT/PI3K pathway is critical for cellular functions and can be stimulated by cytokines and in normal situations. It is involved in regulating various intracellular signal transduction, including development, differentiation, transcriptional regulation, protein, and synthesis. There is a growing body of evidence indicating that miRNAs, which are abundant in exosomes released by different cells, can control cellular biological activities via modulating the PI3K/AKT pathway, hence influencing cancer progression and drug resistance. This article provides an overview of the latest research progress regarding the function and medical use of the PI3K/AKT pathway and exosomal miRNA/AKT/PI3K axis in the behaviors of cancer cells.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02529-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

MicroRNAs (miRNAs) are conserved non-protein-coding RNAs that are naturally present in organisms and can control gene expression by suppressing the translation of mRNA or causing the degradation of mRNA. MicroRNAs are highly concentrated in the PI3K/AKT pathway, and abnormal activation of the PI3K/AKT pathway plays a role in cancer progression. The AKT/PI3K pathway is critical for cellular functions and can be stimulated by cytokines and in normal situations. It is involved in regulating various intracellular signal transduction, including development, differentiation, transcriptional regulation, protein, and synthesis. There is a growing body of evidence indicating that miRNAs, which are abundant in exosomes released by different cells, can control cellular biological activities via modulating the PI3K/AKT pathway, hence influencing cancer progression and drug resistance. This article provides an overview of the latest research progress regarding the function and medical use of the PI3K/AKT pathway and exosomal miRNA/AKT/PI3K axis in the behaviors of cancer cells.

查看原文本刊更多论文

作为人类肿瘤中 PI3K/AKT 通路关键调节因子的外泌体 microRNA。

微RNA（miRNA）是生物体内天然存在的保守的非蛋白编码RNA，可通过抑制mRNA翻译或导致mRNA降解来控制基因表达。微RNA高度集中在PI3K/AKT通路中，而PI3K/AKT通路的异常激活在癌症进展中起着作用。AKT/PI3K 通路对细胞功能至关重要，在正常情况下可受到细胞因子的刺激。它参与调节各种细胞内信号转导，包括发育、分化、转录调节、蛋白质和合成。越来越多的证据表明，不同细胞释放的外泌体中含量丰富的 miRNA 可通过调节 PI3K/AKT 通路控制细胞的生物活性，从而影响癌症的进展和耐药性。本文概述了有关 PI3K/AKT 通路和外泌体 miRNA/AKT/PI3K 轴在癌细胞行为中的功能和医学应用的最新研究进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.